Hold with active 20-25% tactical trim into $64-65; trailing stop $61, hard stop $55.32
Hold is intellectually honest as both bull case (9.7x PE discount, 3.89% dividend, defensive beta, AZN optionality, balance sheet) and bear case (momentum breakdown, EPS credibility risk, pipeline replacement gap, hot CPI) remain live pending Q3 earnings. Execution must be more active than passive Hold — trim 20-25% into $64-65 rather than holding 80-85% residual through cooling momentum regime.
| Position | Action |
|---|---|
| Momentum cooling from overbought; price extended above 50 SMA | Trim 20-25% into $64-65 relief bounce zone (10 EMA retest) |
| Pullback to $58.71-58.75 (50 SMA / lower Bollinger confluence) | Re-engage/add on pullback with hard stop at $55.32 (200 SMA) |
| Close above $67 with positive MACD histogram crossover and volume confirmation | Re-engage/add on breakout above $67 |
BMY is a defensively-positioned mega-cap pharma pivoting through a known LOE event, with $13B in normalized FCF, a 3.89% covered dividend, a deep multi-asset pipeline, an active deleveraging program, and M&A optionality — trading at 9.7x forward earnings.
| Indicator | Value | Signal |
|---|---|---|
| 50 SMA | $58.75 | bullish |
| 200 SMA | $55.32 | bullish |
| 10 EMA | $64.02 | bearish |
| MACD | 1.72 (signal line: 1.84, histogram: -0.12) | bearish |
| RSI | 57.4 (down from 72.8 on Aug 4) | neutral |
| Bollinger Upper Band | $67.01 | bearish |
| Bollinger Lower Band | $58.71 | bullish |
| ATR | $1.78 (up from $1.40 on July 10) | neutral |
Support: 61.5 · 58.75 · 58.71 · 55.32 | Resistance: 68.1 · 67.01 · 65.89 · 64.02
BMY remains in a structural uptrend with the 200 SMA rising from $52.12 in mid-June to $55.32 today and price +15.0% above it, while the 50 SMA at $58.75 and Bollinger lower band at $58.71 form a high-conviction support confluence. Short-term momentum has peaked with MACD declining ~21% from its Aug 4 high of $2.19 to 1.72, and the Aug 3 intraday spike to $68.10 broke above the upper band but failed to sustain—a classic breakout failure. The ATR has expanded 27% from $1.40 to $1.78 in one month, suggesting 2× ATR stops ($3.56) for swing trades and 3× ATR stops ($5.4) for position trades. The preferred strategy is buy-the-dip to the $58.75-$58.71 zone rather than chasing the rally, with new longs only warranted after price reclaims the 10 EMA and shows a fresh MACD histogram positive crossover.
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Close above $67 with positive MACD histogram crossover and volume
Then: Add position
Eliquis LOE is already priced into the 9.7x forward PE; pipeline will replace it
↩ rebuts: “Bear's 'Eliquis death blow' argument”
EV: +$67 (upper Bollinger band retest) → $68.10 (Aug 3 high) → $72+ on Growth Portfolio re-rating; 6–18 month time horizon · concedes: PEG of 2.29 is elevated, but elevated because the market is assigning near-zero credit to the EPS recovery; Negative tangible book value is real on a GAAP basis, though operationally meaningless; Houston capex is a near-term FCF drag, though well within coverage
BMY is a defensive yield name being mistaken for a growth story at current levels. The patent cliff is real, the replacement math doesn't work, and the stock should be sold rather than accumulated.
· concedes: Cobenfy has novel mechanism — show me six quarters of uptake before calling it multi-billion; Reblozyl has solid ramp — but it's a $1-2B asset, not multi-billion; If the deal fails, management credibility and strategic options are further constrained; Structural amortization doesn't mean benign — it's a permanent $3.3B/year drag that won't be 'lapped' as earnings recovery; BMY would be the junior partner in M&A — any control premium would be modest; Houston capex suggests management is trying to position for Cobenfy/Reblozyl/Camzyos ramp — at least they're aware of the problem
→ vs conservative: Hold thesis 'leaves serious money on the table' and is 'intellectually defensible but operationally timid' at current valuation levels
→ vs conservative: Cautious interpretation of Houston announcement as 'weighing on near-term FCF' 'completely misses the signal in the noise' — $2.3B capex is management voting with capital on pipeline conviction
→ vs conservative: AZN skepticism is 'far too dismissive' — free option with asymmetric payoff where cost of being wrong is zero, not a liability
→ vs neutral: MACD negative and 10 EMA break treated as dangerous is 'anchoring to the wrong timeframe' — lower band at $58.71 is actual flush zone, not $63.61 mid-band
Market Cap
$129.94B
PE (TTM)
14.01
Forward PE
9.70
PEG Ratio
2.29
Price/Book
5.82
EV/EBITDA (est.)
~8.7x
Gross Margin
~71%
Operating Margin (TTM)
34.4%
Net Profit Margin
18.9%
ROE
46.6%
ROA
10.7%
ROIC (est.)
~13%
Revenue (TTM)
$49.19B
Revenue (2025)
$48.20B
Revenue (2024)
$48.30B
Revenue (2023)
$45.01B
Revenue (2022)
$46.16B
Net Income (2025)
$7.05B
Net Income (2024)
$(8.95)B
Net Income (2023)
$8.03B
Net Income (2022)
$6.33B
EPS (TTM)
$4.54
Forward EPS
$6.56
2025 Diluted EPS
$3.46
2024 Diluted EPS
$(4.41)
2023 Diluted EPS
$3.86
2022 Diluted EPS
$2.95
R&D Spend
$9.95B
R&D Expense (2025)
$9,951M
R&D Expense (2024)
$11,159M
SG&A Expense (2025)
$7,267M
Restructuring & M&A (2025)
$4,791M
Restructuring & M&A (2024)
$14,342M
Total Assets
$90.04B
Total Debt
$47.14B
Net Debt
$34.90B
Cash & Equivalents
$10.67B
Stockholders' Equity
$18.47B
Net Debt/EBITDA (est.)
~1.8x
Current Ratio
1.53
Tangible Book Value
$(22.63)B
Goodwill
$21.75B
Other Intangibles
$19.35B
Operating Cash Flow
$14.16B
Free Cash Flow (TTM)
$8.11B
Free Cash Flow (2025)
$12.85B
Dividends Paid
$5.05B
CapEx
$1.31B
52W High
$68.10
52W Low
$42.52
50-Day MA
$58.90
200-Day MA
$56.20
Beta
0.225
Dividend Yield
3.89%
Implied EPS Growth
~44%
Strengths
Concerns
Bristol-Myers Squibb Company is a mega-cap pharmaceutical company (market cap $129.94B) trading at an attractive forward PE of 9.7x with ~44% embedded EPS growth (TTM $4.54 to forward $6.56). The company generates strong free cash flow (~$13B annually normalized) and maintains a defensive profile with a low beta of 0.225 and 3.89% dividend yield. However, significant headwinds include flat revenue for 4+ years, the looming Eliquis LOE in 2026 (~25% of total revenue), and high leverage ($47.1B debt) from the 2024 acquisition wave, making this a show-me story dependent on successful commercialization of new launches like Cobenfy and Krazati while managing the patent cliff.
Macro: Risk-off environment ahead of July CPI release (resolves Aug 12); oil prices rising on US-Iran deal doubts; Bitcoin below $64,000; Polymarket strongly pricing no Fed rate cuts in 2026 (86% Yes) with very low US recession odds (8% Yes); implied July annual CPI print around 3.3–3.4% YoY.